Back to top
more

Sucampo Pharmaceuticals, Inc. (SCMP)

(Real Time Quote from BATS)

$18.00 USD

18.00
NA

+0.05 (0.28%)

Updated Feb 13, 2018 03:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bioblast (ORPN) SCA3 Drug Favorable in Phase IIa Study

by Zacks Equity Research

Bioblast (ORPN) announced results from a phase IIa study on trehalose for the treatment of patients with spinocerebellar ataxia type 3.

    Agenus, NCI Ink Deal to Evaluate Prophage-Keytruda Combo

    by Zacks Equity Research

    Agenus (AGEN) entered into a clinical trial collaboration with the National Cancer Institute to evaluate Prophage, in conjunction with Merck's (MRK) Keytruda.

      Benitec Stock Up on Orphan Drug Status for BB-301 in EU

      by Zacks Equity Research

      Benitec (BNTC) announced that its proposed candidate, BB-301, received Orphan Drug Designation in the EU for the treatment of ocularpharyngeal muscular dystrophy.

        Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals

        by Zacks Equity Research

        Zacks.com featured highlights: Glaukos, Daqo New Energy, Calavo Growers and Sucampo Pharmaceuticals

          Key FDA Events to Watch Out for in Q1

          by Zacks Equity Research

          Two important regulatory events scheduled in the first quarter of 2017.

            4 Profitable Stocks with Amazingly High Returns

            by Zacks Equity Research

            Net income ratio gives us the exact profitability level of a company and reflects the percentage of net income to total sales revenue.

              Novartis to Conduct Trial on Obese, Type II Diabetes Patients

              by Zacks Equity Research

              In a recent announcement, MorphoSys AG mentioned that its partner Swiss major Novartis AG (NVS) will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes.

                Coherus Offers Positive Phase III Data on Humira Biosimilar

                by Zacks Equity Research

                Coherus BioSciences, Inc. (CHRS) reported encouraging top-line data from an ongoing part 3, of a phase III study on its biosimilar version of AbbVie Inc.'s (ABBV) Humira (adalimumab), CHS-1420, for the treatment of patients with psoriasis.

                  TESARO Varubi IV Gets Complete Response Letter in the U.S.

                  by Zacks Equity Research

                  TESARO (TSRO) announced that it has received a Complete Response Letter from the FDA regarding its NDA for Varubi IV.

                    TherapeuticsMD's Rejoice Study Data Published in Journal

                    by Zacks Equity Research

                    TherapeuticsMD, Inc. (TXMD) announced the publication of two manuscripts detailing with the results of the company's pivotal phase III study (Rejoice) in Menopause: The Journal of The North American Menopause Society.

                      Merck KGaA, Vertex Announce Tie-Up for Oncology Programs

                      by Zacks Equity Research

                      Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.

                        Mylan/Biocon's Herceptin Biosimilar under Review in the U.S.

                        by Zacks Equity Research

                        Mylan (MYL) and Biocon Ltd. announced that the FDA had accepted the BLA for their biosimilar version of Herceptin (trastuzumab), MYL-1401O.

                          Valeant Streamlines Portfolio with Skincare Brands Sale

                          by Zacks Equity Research

                          Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it has entered into an agreement to sell its CeraVe, AcneFree and AMBI skincare brands to L'Or??al for $1.3 billion in cash.

                            The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America

                            by Zacks Equity Research

                            The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Insulet, Western Refining, PennyMac Mortgage Investment Trust and Extended Stay America

                              Novo Nordisk (NVO) Fiasp Gets EU Nod for Diabetes in Adults

                              by Zacks Equity Research

                              Novo Nordisk (NVO) announced that its fast-acting insulin aspart, Fiasp, has been approved in the EU for the treatment of diabetes in adults.

                                5 Underperformers of 2016: Turnaround Story in 2017?

                                by Zacks Equity Research

                                Based on strong fundamentals, strategic implementation, planned execution, and certain positive catalysts, these five stocks carry a huge upside potential and a high probability of outperforming the S&P 500 market index in the coming days.

                                  Valeant to Sell Dendreon Unit to Sanpower for $820 Million

                                  by Zacks Equity Research

                                  Beleaguered Valeant Pharmaceuticals International, Inc. (VRX) announced that it will sell all the outstanding equity interests in Dendreon Pharmaceuticals, Inc. to the China based Sanpower Group Co., Ltd.

                                    Zacks.com featured highlights: NVIDIA, Sucampo Pharmaceuticals, Calavo Growers, Tucows and E*TRADE Financial

                                    by Zacks Equity Research

                                    Zacks.com featured highlights: NVIDIA, Sucampo Pharmaceuticals, Calavo Growers, Tucows and E*TRADE Financial

                                      Roche Gets Priority Review for Immunotherapy Drug Tecentriq

                                      by Zacks Equity Research

                                      Roche Holding AG's (RHHBY) Genentech announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for cancer immunotherapy, Tecentriq.

                                        Merrimack (MACK) Sells Onivyde Rights to Ipsen for $1B

                                        by Zacks Equity Research

                                        Merrimack Pharmaceuticals, Inc. (MACK) announced that it has entered into an agreement with Ipsen for $1.0 billion for Onivyde.

                                          Go Driehaus Way: 5 Momentum Picks

                                          by Zacks Equity Research

                                          Richard Driehaus, a pioneer in momentum investing, developed a strategy that has the potential to yield impressive returns.

                                            Top Ranked Growth Stocks to Buy for January 6th

                                            by Zacks Equity Research

                                            Here are four stocks with buy ranks and strong growth characteristics for investors to consider today, January 6th:

                                              The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

                                              by Zacks Equity Research

                                              The Zacks Analyst Blog Highlights: Sucampo Pharmaceuticals, Dr. Reddy's Laboratories, BioMarin Pharmaceutical and Repligen

                                                Why Sucampo Pharmaceuticals (SCMP)Could Be an Impressive Growth Stock

                                                by Zacks Equity Research

                                                Sucampo Pharmaceuticals (SCMP) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective

                                                  Is Valeant (VRX) Fated for Terrible 2017 As Well?

                                                  by Zacks Equity Research

                                                  Shares of Valeant Pharmaceuticals, Inc. (VRX) slumped 85.3% in 2016, eroding a chunk of shareholders' net worth.